Works matching B-cell maturation antigen (BCMA)

Results: 357
    1

    CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.

    Published in:
    Vaccines, 2023, v. 11, n. 11, p. 1721, doi. 10.3390/vaccines11111721
    By:
    • Mishra, Abhinava K.;
    • Gupta, Ashna;
    • Dagar, Gunjan;
    • Das, Dayasagar;
    • Chakraborty, Abhijit;
    • Haque, Shabirul;
    • Prasad, Chandra Prakash;
    • Singh, Archana;
    • Bhat, Ajaz A.;
    • Macha, Muzafar A.;
    • Benali, Moez;
    • Saini, Kamal S.;
    • Previs, Rebecca Ann;
    • Saini, Deepak;
    • Saha, Dwaipayan;
    • Dutta, Preyangsee;
    • Bhatnagar, Aseem Rai;
    • Darswal, Mrinalini;
    • Shankar, Abhishek;
    • Singh, Mayank
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9

    S196: ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM‐3.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967696.13096.54
    By:
    • Mohty, Mohamad;
    • Tomasson, Michael H.;
    • Arnulf, Bertrand;
    • Bahlis, Nizar J;
    • Rodríguez‐Otero, Paula;
    • Martinez‐Lopez, Joaquín;
    • Touzeau, Cyrille;
    • Quach, Hang;
    • Depaus, Julien;
    • Yokoyama, Hisayuki;
    • Manier, Salomon;
    • Raje, Noopur;
    • Raab, Marc S.;
    • Searle, Emma;
    • Leip, Eric;
    • Sullivan, Sharon T.;
    • Czibere, Akos;
    • Viqueira, Andrea;
    • Lesokhin, Alexander
    Publication type:
    Article
    10

    P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

    Published in:
    2023
    By:
    • Sidana, Surbhi;
    • Moreau, Philippe;
    • Garfall, Alfred;
    • Bhutani, Manisha;
    • Oriol, Albert;
    • Nooka, Ajay;
    • Martin, Tom;
    • Rosiñol Dachs, Laura;
    • Mateos, Maria-Victoria;
    • Bahlis, Nizar J;
    • Popat, Rakesh;
    • Besemer, Britta;
    • Martinez-Lopez, Joaquín;
    • Krishnan, Amrita;
    • Delforge, Michel;
    • Trancucci, Danielle;
    • Verona, Raluca;
    • Stephenson, Tara;
    • Chastain, Katherine;
    • van de Donk, Niels W.C.J.
    Publication type:
    Abstract
    11

    P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES.

    Published in:
    2023
    By:
    • Manier, Salomon;
    • Lesokhin, Alexander;
    • Mohty, Mohamad;
    • Niesvizky, Ruben;
    • Maisel, Christopher;
    • Arnulf, Bertrand;
    • Larson, Sarah M.;
    • Nina Varshavsky-Yanovsky, Asya;
    • Leleu, Xavier;
    • Karlin, Lionel;
    • Vesole, David H.;
    • Bahlis, Nizar J;
    • Fernandez de Larrea, Carlos;
    • Raje, Noopur;
    • Leip, Eric;
    • Sullivan, Sharon T.;
    • Elmeliegy, Mohamed;
    • Viqueira, Andrea;
    • Nooka, Ajay
    Publication type:
    Abstract
    12
    13
    14
    15
    16

    P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON‐CELLULAR ANTI‐B‐CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY.

    Published in:
    HemaSphere, 2023, v. 7, p. 25, doi. 10.1097/01.HS9.0000936240.43628.7e
    By:
    • van de Donk, N.;
    • Mateos, M.‐V.;
    • Cohen, Y.C.;
    • Rodriguez‐Otero, P.;
    • Paiva, B.;
    • Cohen, A.D.;
    • Martin, T.;
    • Suvannasankha, A.;
    • Madduri, D.;
    • Corsale, C.;
    • Schecter, J.M.;
    • De Braganca, K.C.;
    • Jackson, C.C.;
    • Varsos, H.;
    • Deraedt, W.;
    • Roccia, T.;
    • Mistry, P.;
    • Xu, X.;
    • Li, K.;
    • Zudaire, E.
    Publication type:
    Article
    17

    P32 MAJESTEC‐1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B‐CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

    Published in:
    HemaSphere, 2023, v. 7, p. 28, doi. 10.1097/01.HS9.0000936256.84340.a7
    By:
    • van de Donk, N.;
    • Cortes‐Selva, D.;
    • Casneuf, T.;
    • Vishwamitra, D.;
    • Stein, S.;
    • Perova, T.;
    • Ramos, E.;
    • Van Steenbergen, L.;
    • Boominathan, R.;
    • Lau, O.;
    • Davis, C.;
    • Banerjee, A.;
    • Stephenson, T.;
    • Uhlar, C.;
    • Kobos, R.;
    • Goldberg, J.;
    • Pei, L.;
    • Trancucci, D.;
    • Girgis, S.;
    • Lin, S.X.W.
    Publication type:
    Article
    18

    P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3.

    Published in:
    HemaSphere, 2022, v. 6, p. 839, doi. 10.1097/01.HS9.0000846664.78859.dd
    By:
    • Lesokhin, A. M.;
    • Arnulf, B.;
    • Niesvizky, R.;
    • Mohty, M.;
    • Bahlis, N. J.;
    • Tomasson, M. H.;
    • Rodrίguez‐Otero, P.;
    • Quach, H.;
    • Raje, N. S.;
    • Iida, S.;
    • Raab, M.‐S.;
    • Czibere, A.;
    • Sullivan, S.;
    • Leip, E.;
    • Viqueira, A.;
    • Leleu, X.
    Publication type:
    Article
    19

    S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B‐CELL MATURATION ANTIGEN (BCMA)‐TARGETED AGENTS.

    Published in:
    HemaSphere, 2022, v. 6, p. 85, doi. 10.1097/01.HS9.0000843628.63947.e4
    By:
    • Touzeau, C.;
    • Krishnan, A.;
    • Moreau, P.;
    • Perrot, A.;
    • Usmani, S. Z.;
    • Manier, S.;
    • Cavo, M.;
    • Martinez‐Chamorro, C.;
    • Nooka, A.;
    • Martin, T.;
    • Karlin, L.;
    • Leleu, X.;
    • Bahlis, N.;
    • Besemer, B.;
    • Pei, L.;
    • Verona, R.;
    • Girgis, S.;
    • Uhlar, C.;
    • Kobos, R.;
    • Garfall, A.
    Publication type:
    Article
    20
    21
    22
    23

    OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02100-5
    By:
    • Dholaria, Bhagirathbhai;
    • Bahlis, Nizar;
    • Raje, Noopur;
    • Costello, Caitlin;
    • Solh, Melhem;
    • Levy, Moshe;
    • Tomasson, Michael;
    • Dube, Harman;
    • Damore, Michael;
    • Hoi Kei Lon;
    • Basu, Cynthia;
    • Skoura, Athanasia;
    • Chan, Edward;
    • Trudel, Suzanne;
    • Jakubowiak, Andrzej;
    • Chu, Michael;
    • Gasparetto, Cristina;
    • Dalovisio, Andrew;
    • Sebag, Michael;
    • Lesokhin, Alexander
    Publication type:
    Article
    24

    MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S439, doi. 10.1016/S2152-2650(21)01978-9
    By:
    • Levy, Moshe;
    • Bahlis, Nizar;
    • Raje, Noopur;
    • Costello, Caitlin;
    • Dholaria, Bhagirathbhai;
    • Solh, Melhem;
    • Tomasson, Michael;
    • Dube, Harman;
    • Damore, Michael;
    • Hoi Kei Lon;
    • Basu, Cynthia;
    • Skoura, Athanasia;
    • Chan, Edward;
    • Trudel, Suzanne;
    • Jakubowiak, Andrzej;
    • Chu, Michael;
    • Gasparetto, Cristina;
    • Dalovisio, Andrew;
    • Sebag, Michael;
    • Lesokhin, Alexander
    Publication type:
    Article
    25

    MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S422, doi. 10.1016/S2152-2650(21)01946-7
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    26

    Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01578-0
    By:
    • Levy, Moshe;
    • Bahlis, Nizar;
    • Raje, Noopur;
    • Costello, Caitlin;
    • Dholaria, Bhagirathbhai;
    • Solh, Melhem;
    • Tomasson, Michael;
    • Dube, Harman;
    • Damore, Michael;
    • Lon, Hoi Kei;
    • Basu, Cynthia;
    • Skoura, Athanasia;
    • Chan, Edward;
    • Trudel, Suzanne;
    • Jakubowiak, Andrzej;
    • Chu, Michael;
    • Gasparetto, Cristina;
    • Dalovisio, Andrew;
    • Sebag, Michael;
    • Lesokhin, Alexander
    Publication type:
    Article
    27

    Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01569-X
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    28

    Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01275-1
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Yi Lin;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    29
    30
    31

    In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation.

    Published in:
    International Journal of Molecular Sciences, 2024, v. 25, n. 3, p. 1394, doi. 10.3390/ijms25031394
    By:
    • Jiang, Genqiao;
    • Neuber, Brigitte;
    • Hückelhoven-Krauss, Angela;
    • Höpken, Uta E.;
    • Ding, Yuntian;
    • Sedloev, David;
    • Wang, Lei;
    • Reichman, Avinoam;
    • Eberhardt, Franziska;
    • Wermke, Martin;
    • Rehm, Armin;
    • Müller-Tidow, Carsten;
    • Schmitt, Anita;
    • Schmitt, Michael
    Publication type:
    Article
    32
    33
    34
    35
    36

    Les anticorps bispécifiques.

    Published in:
    Hematologie, 2021, v. 27, p. 19, doi. 10.1684/hma.2021.1650
    By:
    • Le Grand, Sophie;
    • Perrot, Aurore
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43
    44

    Deciphering the genetics and mechanisms of predisposition to multiple myeloma.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-50932-7
    By:
    • Went, Molly;
    • Duran-Lozano, Laura;
    • Halldorsson, Gisli H.;
    • Gunnell, Andrea;
    • Ugidos-Damboriena, Nerea;
    • Law, Philip;
    • Ekdahl, Ludvig;
    • Sud, Amit;
    • Thorleifsson, Gudmar;
    • Thodberg, Malte;
    • Olafsdottir, Thorunn;
    • Lamarca-Arrizabalaga, Antton;
    • Cafaro, Caterina;
    • Niroula, Abhishek;
    • Ajore, Ram;
    • Lopez de Lapuente Portilla, Aitzkoa;
    • Ali, Zain;
    • Pertesi, Maroulio;
    • Goldschmidt, Hartmut;
    • Stefansdottir, Lilja
    Publication type:
    Article
    45
    46
    47

    Early Cytomegalovirus Reactivation in Renal Recipients Is Associated with High Levels of B Cell Maturation Antigen Transcript Expression Prior to Transplantation.

    Published in:
    International Journal of Molecular Sciences, 2023, v. 24, n. 13, p. 10491, doi. 10.3390/ijms241310491
    By:
    • Alfaro, Rafael;
    • Rodríguez-Aguilar, Luis;
    • Llorente, Santiago;
    • Jimenez-Coll, Victor;
    • Martínez-Banaclocha, Helios;
    • Galián, José Antonio;
    • Botella, Carmen;
    • Moya-Quiles, María Rosa;
    • Muro-Perez, Manuel;
    • Minguela, Alfredo;
    • Legaz, Isabel;
    • Muro, Manuel
    Publication type:
    Article
    48
    49

    Cellular Therapies for Multiple Myeloma: Engineering Hope.

    Published in:
    Cancers, 2024, v. 16, n. 22, p. 3867, doi. 10.3390/cancers16223867
    By:
    • Vera-Cruz, Sarah;
    • Jornet Culubret, Maria;
    • Konetzki, Verena;
    • Alb, Miriam;
    • Friedel, Sabrina R.;
    • Hudecek, Michael;
    • Einsele, Hermann;
    • Danhof, Sophia;
    • Scheller, Lukas
    Publication type:
    Article
    50